Phantom Neuro, a neurotech company focused on human-machine interfaces, has raised $19 million in a funding round led by Ottobock, which specializes in prosthetics, orthotics and exoskeleton technology. This latest round brings Phantom Neuro’s total funding to $28 million, which will be used to advance the company’s Phantom X robotic control platform. The funds will enable preclinical testing, first-in-human clinical trials, regulatory submissions and expanded research and development.
In addition to Ottobock, the Series A round included existing investors like Breakout Ventures, Draper Associates and LionBird Ventures along with new investors such as Actual VC, METIS Innovative and e1 Ventures.
As part of the deal, Ottobock will also join Phantom Neuro’s board of directors to support the company’s commercialization efforts.
“For decades, Ottobock has been at the forefront of restoring mobility for millions of people. By partnering with them, we're accelerating Phantom X’s path to market and laying the groundwork for the future we all desire, where assistive devices truly function as natural extensions of the human body,” Dr. Connor Glass, CEO of Phantom Neuro, said in a statement.
